Rucaparib is a targeted therapy drug for specific gene mutation-related cancers, mainly used for maintenance therapy of ovarian and prostate cancers. This article will systematically expound the core information of the drug from three aspects: its role and efficacy, dosage, side effects and precautions, so as to help patients and medical practitioners fully understand the clinical application of the drug.

Instructions for Rucaparib: action and efficacy

Rucaparib exerts anti-tumor effects by inhibiting specific enzyme activity and is indicated for cancer patients harboring BRCA gene mutations. Its precise targeting mechanism provides a new treatment option for patients with advanced disease.

Indications and Targets

Rucaparib was approved for the maintenance treatment of BRCA-mutated recurrent ovarian cancer and metastatic castration-resistant prostate cancer. Its targets are PARP1, PARP2 and PARP3 enzymes, which induce apoptosis in tumor cells by blocking the DNA repair pathway.

R&D background and pharmacological properties

The drug was developed by Clovis Oncology in the United States and approved by the FDA in 2016. Its main ingredient is Rucaparib, which inhibits the activity of PARP enzyme and leads to the accumulation of DNA damage in tumor cells, and ultimately inhibits cancer cell proliferation.

The targeting of Rucaparib makes it effective in patients with gene mutations, while reducing the damage to normal cells, providing an important breakthrough in the treatment of advanced cancer.

Dosage of Rucaparib Dosage

Standardized medication is the key to confirming efficacy and safety. Patients should follow the dosage requirements strictly and adjust the treatment regimen with medical monitoring.

Recommended dosage and administration

600 mg (two 300 mg tablets) orally twice daily for a total dose of 1200 mg. The time of taking the drug is not restricted by diet, and there is no need to make up if the dose is missed, and there is no need to adjust the dose after vomiting. Treatment should be continued until disease progression or intolerable toxicity occurs.

Dose adjustment with special populations

Adverse effects can be discontinued or dose reduced, and the specific regimen needs to be evaluated by a physician. Patients with mild to moderate impairment of renal function or liver function do not require dose adjustment, but caution should be exercised in patients with severe hepatic and renal insufficiency. There was no significant difference in drug safety data between elderly patients and younger patients.

Rational drug use needs to be dynamically adjusted according to individual differences, and regular monitoring of liver and kidney function and blood indicators is a necessary measure to reduce the risk.

Side effects and precautions of Rucaparib

Despite the targeted advantages of Rucaparib, it is still necessary to be vigilant for potential adverse reactions and contraindications to determine the safety of treatment.

Common adverse reactions

Ovarian cancer patients often have symptoms such as nausea, fatigue, anemia, and thrombocytopenia; Prostate cancer patients are more likely to experience fatigue, rashes, and decreased appetite. Approximately 10% to 20% of patients may develop abnormal liver function or hematologic toxicity, and regular monitoring is required.

Contraindications to drug interactions

Pregnant and lactating women should not be used, as it may cause fetal malformations or affect the health of the baby. Concomitant use with CYP enzyme inhibitors (eg, amiodarone, rifampicin) may enhance the toxicity of other drugs, and should be avoided or dose adjusted. Long-term use should be vigilant for rare serious reactions such as myelodysplastic syndrome.

Strict adherence to medication guidelines, regular medical evaluations, and lifestyle management are core strategies to reduce the risk of treatment, and patients need to maintain close communication with the medical team.